| 摘要: |
| 目的 基于WHO公布的2022年全球癌症统计报告，描述和分析全球及中国前列腺癌的发病及死亡状况。方法 基于2022全球癌症统计数据，系统性描述全球及中国前列腺癌的发病人数、粗发病率、标化发病率（SIR）、死亡人数、粗死亡率和标化死亡率（SMR），并根据年龄及人类发展指数（HDI）进行分层分析。使用Pearson相关分析评估SIR、SMR及死亡发病比（M/I）与HDI之间的相关性。结果 2022年，全球前列腺癌新发病人数共有146.7万，SIR为29.4/10万，在男性人群所有癌种中排第2位；全球前列腺癌死亡人数为39.7万，SMR为7.3/10万，在男性所有癌种中排第5位。2022年，中国前列腺癌新发病人数为13.4万，SIR为9.7/10万，SMR为3.3/10万，在中国男性人群所有癌种中均排第7位。全球前列腺癌的发病人数和SIR从45岁开始快速增长，死亡人数及SMR从50岁开始呈快速增长趋势；中国前列腺癌的发病人数和SIR自60岁开始快速增长，死亡人数和SMR从65岁开始快速增长。中国前列腺癌的M/I为0.337，在HDI高水平国家和地区中排第30位。Pearson相关分析显示，前列腺癌SIR与HDI（r＝0.440，P＝0.008）呈正相关，M/I与HDI呈负相关（r＝－0.877，P＜0.001），而SMR与HDI无关（P＞0.05）。结论 全球前列腺癌的疾病负担严重。中国前列腺癌的发病率呈逐步上升态势，且存在死亡率高的特点。积极开展前列腺癌早筛、优化多学科协作诊疗模式及全程化管理可提高前列腺癌的诊疗水平，改善患者预后。 |
| 关键词: 前列腺肿瘤 流行病学 全球 中国 |
| DOI：10.16781/j.CN31-2187/R.20240685 |
| 投稿时间：2024-10-10修订日期：2024-10-24 |
| 基金项目:国家自然科学基金（82203485）． |
|
| Prostate cancer in the world and China in 2022: an epidemiological analysis |
| QU Min,GAO Xu* |
(Department of Urology, The First Affiliated Hospital of Naval Medical University (Second Military Medical University), Shanghai 200433, China
*Corresponding author) |
| Abstract: |
| Objective To analyze the incidence and mortality of prostate cancer (PCa) in the world and China based on the data of 2022 global cancer statistics published by the World Health Organization (WHO). Methods Based on the data of 2022 global cancer statistics, the number of incident cases, crude incidence, standardized incidence rate (SIR), number of deaths, crude mortality, and standardized mortality rate (SMR) of PCa in the world and China were systematically described, and stratified according to the age and human development index (HDI). Pearson correlation analysis was applied to evaluate the correlations of SIR, SMR, and mortality-to-incidence ratio (M/I) with HDI. Results In 2022, there were 1 467 000 new cases of PCa in the world, with an SIR of 29.4/100 000, ranking the 2nd among all cancer types in the males; the number of deaths in the world was 397 000, with an SMR of 7.3/100 000, ranking the 5th among all cancer types in males. In 2022, the number of new PCa cases in China was 134 000, with an SIR of 9.7/100 000 and an SMR of 3.3/100 000, both ranking the 7th among males. The number of new PCa cases and SIR in the world increased rapidly from 45 years of age, and the number of deaths and SMR showed a rapid growth trend from 50 years of age; the number of new PCa cases and SIR in China increased rapidly from 60 years of age, and the number of deaths and SMR increased rapidly from 65 years of age. The M/I of PCa in China was 0.337, ranking the 30th among countries and territories with high HDI. Pearson correlation analysis showed that SIR was positively correlated with HDI (r＝0.440, P＝0.008), M/I were negatively correlated with HDI (r＝－0.877, P＜0.001), while SMR was not correlated with HDI (P＞0.05). Conclusion The burden of PCa is heavy in the world. The incidence of PCa in China is gradually increasing, and it is characterized by high mortality. Actively carrying out early screening of PCa, optimizing the diagnosis and treatment mode with multidisciplinary collaboration, and achieving the whole process management can improve the diagnosis, treatment and prognosis of patients. |
| Key words: prostatic neoplasms epidemiology global China |
